Challenging the EAU Guidelines on Non–Muscle-Invasive Bladder Cancer (NMIBC): Single Instillation of Chemotherapy After Transurethral Resection of NMIBC and Chemotherapy Versus Bacillus Calmette-Guérin in Treatment of Intermediate-Risk Tumours

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology Web site. http://www.uroweb.org/professional-resources/guidelines/online. Oosterlinck, 2005, Low-grade Ta (noninvasive) urothelial carcinoma of the bladder, Urology, 66, 75, 10.1016/j.urology.2005.07.063 Nieder, 2005, Management of stage T1 tumours of the bladder: international consensus panel, Urology, 66, 108, 10.1016/j.urology.2005.08.066 Sylvester, 2005, High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder, Urology, 66, 90, 10.1016/j.urology.2005.06.135 Bladder Cancer Clinical Guideline Update Panel. Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. American Urological Association Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bc. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer including upper tract tumors and urothelial carcinoma of the prostate. NCCN Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Herr, 1997, High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumour, Semin Urol Oncol, 15, 142 Sylvester, 2004, A single immediate post-operative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials, J Urol, 171, 2186, 10.1097/01.ju.0000125486.92260.b2 Brausi, 2008, Approaches to the management of non-muscle invasive bladder cancer: a review of current guidelines and best practice recommendations from the International Bladder Cancer Group, Eur Urol Suppl, 7, 615, 10.1016/j.eursup.2008.07.001 Dobruch, 2009, Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?, BJU Int, 104, 170, 10.1111/j.1464-410X.2009.08654.x Kaasinen, 2002, Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma, Eur Urol, 42, 167, 10.1016/S0302-2838(02)00260-9 Oddens, 2004, One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?, Eur Urol, 46, 336, 10.1016/j.eururo.2004.05.003 Zincke, 1983, Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial, J Urol, 129, 505, 10.1016/S0022-5347(17)52205-3 Cai, 2008, Can early single dose instillation of epirubicin improve bacillus Calmette-Guérin efficacy in patients with non-muscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study, J Urol, 180, 110, 10.1016/j.juro.2008.03.038 Berrum-Svennung, 2008, A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences, J Urol, 179, 101, 10.1016/j.juro.2007.08.166 Solsona, 1999, Effectiveness of a single immediate mitomycin C instillation in patients with low-risk superficial bladder cancer: short and long-term follow-up, J Urol, 161, 1120, 10.1016/S0022-5347(01)61606-9 Gudjónsson, 2009, Should all patients with non–muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study, Eur Urol, 55, 773, 10.1016/j.eururo.2009.01.006 Sylvester, 2002, Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials, J Urol, 168, 1964, 10.1016/S0022-5347(05)64273-5 Böhle, 2004, Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression, Urology, 63, 682, 10.1016/j.urology.2003.11.049 Malmström, 2009, An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer, Eur Urol, 56, 247, 10.1016/j.eururo.2009.04.038 Järvinen, 2009, Eur Urol, 56, 260, 10.1016/j.eururo.2009.04.009 Sylvester RJ, Brausi MA, Hoelti W, et al. Long-term efficacy results of EORTC GU Group study 30911 comparing epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage TaT1 papillary carcinoma of the bladder. Eur Urol Suppl 2008; 3:298. Abstract 907. Pawinski, 1996, J Urol, 156, 1934, 10.1016/S0022-5347(01)65396-5